Zoran Zdraveski
Algemeen Adviseur bij TSCAN THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-05-2024
Actieve functies van Zoran Zdraveski
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| TSCAN THERAPEUTICS, INC. | Algemeen Adviseur | 09-09-2021 | - |
| Bedrijfssecretaris | 09-09-2021 | - |
Loopbaan van Zoran Zdraveski
Eerdere bekende functies van Zoran Zdraveski
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| MAGENTA THERAPEUTICS | Algemeen Adviseur | 01-04-2017 | 01-04-2021 |
| Bedrijfssecretaris | 01-03-2018 | 01-04-2021 | |
| EPIZYME, INC. | Corporate Officer/Principal | 01-07-2012 | 01-04-2017 |
Opleiding van Zoran Zdraveski
| Massachusetts Institute of Technology | Doctorate Degree |
| Suffolk University Law School | Graduate Degree |
| Southern Methodist University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| General Counsel | 2 |
| Corporate Secretary | 2 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Zoran Zdraveski
- Ervaring
